Skip to main navigation
Skip to main content
Skip to Footer
English
Français
Canada
Répertoire du site Sandoz
Our Work
What We Do
Quality Generics
Biopharmaceuticals
Specialty Products
About Us
Who We Are
Corporate Responsibility
Doing Business Responsibly
Contact Us
Grants, Donations and Sponsorships
Products
Consumers
Patients
Healthcare Professionals
Patient Support Programs
News
Media Releases
Media Resource Center
Stay Up-To-Date
Careers
Available Positions
Diversity & Inclusion
Our Benefits
Sandoz-Connect Portal
Search
All News
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Media Releases
Filter By
2022
April
Media Release
/
Apr 26, 2022
Novartis Q1 2022 Financial Results
Read More
Media Release
/
Apr 08, 2022
New Sandoz-Connect Portal
Read More
March
Media Release
/
Mar 10, 2022
Novartis expands humanitarian efforts in Ukraine through donation of essential medicines
Read More
Media Release
/
Mar 01, 2022
Sandoz Canada Completes Sale of Sterile Injectable Medicine Manufacturing Plant
Read More
Media Release
/
Mar 01, 2022
Sandoz Canada Completes Sale of Sterile Injectable Medicine Manufacturing Plant
Read More
February
Media Release
/
Feb 03, 2022
Novartis 2021 Annual Reporting
Read More
2021
October
Media Release
/
Oct 27, 2021
Novartis Q3 2021 Financial Results
Read More
Media Release
/
Oct 04, 2021
Sandoz Canada launches PrSandoz® Dimethyl Fumarate Delayed-Release Capsules, a generic equivalent to PrTecfidera
Read More
September
Media Release
/
Sep 01, 2021
Sandoz Canada launches PrSandoz® Lenalidomide, a generic equivalent to PrRevlimid®
Read More
June
Media Release
/
Jun 02, 2021
Biosimilars reimbursement update: Ontario adds Inclunox™ to its list of reimbursed drugs
Read More
Search Results Navigation
Current page
1
of 5
Page
2
of 5
Page
3
of 5
Page
4
of 5
Page
5
of 5
…
Next page
next ›
Last page
last »
Twitter
Tweet
Facebook
Share
Share
Twitter
Facebook
LinkedIn
Email
Jump to Comments
You are here
Home
›
